Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Cash: 2012-2025

Historic Change in Cash for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to -$109.9 million.

  • CorMedix's Change in Cash fell 1729.56% to -$109.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 153.55%. This contributed to the annual value of -$3.1 million for FY2024, which is 783.93% down from last year.
  • As of Q3 2025, CorMedix's Change in Cash stood at -$109.9 million, which was down 218.18% from $93.0 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Change in Cash ranged from a high of $93.0 million in Q2 2025 and a low of -$109.9 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Cash was -$674,966 (2024), whereas its average is -$1.5 million.
  • Examining YoY changes over the last 5 years, CorMedix's Change in Cash showed a top increase of 1,485.33% in 2025 and a maximum decrease of 1,729.56% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Change in Cash stood at -$13.0 million in 2021, then spiked by 99.27% to -$95,334 in 2022, then slumped by 125.42% to -$17.9 million in 2023, then skyrocketed by 52.66% to $5.4 million in 2024, then slumped by 1,729.56% to -$109.9 million in 2025.
  • Its Change in Cash was -$109.9 million in Q3 2025, compared to $93.0 million in Q2 2025 and $25.6 million in Q1 2025.